Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
09/30/24, 11:11 AM
Location
cambridgeMoney
$110 million
Industry
biotechnology
Type
agreement
Prime Medicine, Inc. has announced a strategic research collaboration and license agreement with Bristol Myers Squibb for the development and commercialization of multiple Prime Edited Ex Vivo T-Cell Therapies. The collaboration combines Prime Medicine’s gene editing capabilities with Bristol Myers Squibb’s expertise in novel cell therapies.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
Related People
Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Ah
Ah • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more